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Summary
Chronic myeloid leukaemia in children and young people is a
relatively rare form of leukaemia that shows increased inci-
dence with age and some evidence suggests that the molecular
basis differs from that in adults. Significant advances in
targeted therapy with the development and use in children of
tyrosine kinase inhibitors and the ability to monitor and
understand the prognostic significance of minimal residual
disease by standardized molecular techniques has shifted the
management of this condition from bone marrow transplan-
tation as the main therapeutic modality to individualized
treatment for each patient based on achieving specific mile-
stones. The physiological changes occurring during childhood,
particularly those affecting growth and development and the
long-term use of treatment, pose specific challenges in this
age group, which we are only beginning to understand.
Keywords: chronic myeloid leukaemia, children, tyrosine
kinase inhibitor, stem cell transplantation, BCR-ABL1.
Chronic myeloid leukaemia (CML) constitutes 2–3% of leu-
kaemias in children and has an incidence of 06–12/million
children/year. Its incidence increases with age: it is exception-
ally rare in infancy, 07/million children/year for patients
aged 1–14 years and 12/million children/year in adolescents.
As in adults, there is an increased prevalence in males
(12:1). The median age at presentation is 11 years. Children
tend to present with higher white blood cell counts (WBC)
than adults, with a median WBC of 242 9 109/l (Millot
et al, 2005). Approximately 10% of cases present in advanced
phase, a higher proportion than reported in adults (Suttorp
& Millot, 2010).
Although there is some evidence that the molecular basis
of CML in children may be different from that in adults
(Krumbholz et al, 2012), limited data (Cwynarski et al, 2003;
Millot et al, 2005) indicate that 90–95% of children that
present with clinical and morphological features of CML are
Philadelphia chromosome-positive (Ph+), i.e. their haemo-
poietic cells carry the characteristic reciprocal translocation t
(9;22)(q34;q11), which leads to the formation of a BCR-
ABL1 fusion gene and protein. Around half of the remainder
also have the BCR-ABL1 fusion gene despite the absence of a
detectable t(9;22) by conventional cytogenetics. The only def-
inite aetiological factor in CML is ionizing radiation (Andoli-
na et al, 2012) and there is no clear familial predisposition
or link to immune suppression, although isolated case
reports have been published of childhood CML in twins
(Kosenow & Pfeiffer, 1969), Down syndrome (Cawein et al,
1965), after renal transplant (Sanz et al, 1996) and in human
immunodeficiency virus (HIV) infection (Setty et al, 2009).
In the pre-tyrosine kinase inhibitor era, adults with CML
treated with hydroxycarbamide or interferon-alpha (IFN-a)
had a median survival in the region of 5 years and a 10-year
survival of 5% (Hehlmann et al, 1994). The median duration
of chronic phase (CP) in haematological remission without i-
matinib is 4 years (Ozer et al, 1993). Once accelerated phase
(AP) has developed the median time to transformation to
blast crisis (BC) is 6–18 months. Median survival in BC is 3–
9 months. The rate of transformation to BC has been esti-
mated at 20–35% per year on hydroxycarbamide/busulphan,
10–20% for patients on IFN-a and 1–15% per year for
patients on imatinib (Silver et al, 1999; Druker et al, 2006).
The risk of transformation on imatinib is time and response
dependent with a decreasing risk of progression and a cumu-
lative incidence AP, BC and death of 5% (Hehlmann et al,
2011). There is no evidence that the natural history in
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children is significantly different, although published studies
are small (Champagne et al, 2004; Millot et al, 2005).
This document outlines a suggested management
approach for children and young people up to the age of
18 years with CML based where possible on paediatric data,
but necessarily relying mainly on data from studies in adults.
The aim of these guidelines is to have a uniform manage-
ment approach and to establish the clinical situations in
which novel therapies should be considered, preferably in
international clinical trials.
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Trephine biopsy (for fibrosis, cellularity,
transformation), but not mandatory
Immunophenotyping (if BC)
Other baseline investigations:
1 Reverse transcription polymerase chain reaction (RT-
PCR) for BCR-ABL1 (to determine breakpoint in Ph+
cases for later monitoring and to investigate molecular
diagnosis in Ph cases). Results to be expressed accord-
ing to the international recommendations for harmoniz-
ing methodology (Hughes et al, 2006)
2 tyrosine kinase domain mutation analysis at diagnosis is
only indicated for AP/BC
3 human leucocyte antigen (HLA)-type patient (high reso-
lution) and family
4 blood group
5 virology: cytomegalovirus, hepatitis B/C virus, HIV, vari-
cella zoster virus, Epstein–Barr virus
6 biochemistry: urea and electrolytes, creatinine, urate,
liver function tests, Ca/PO4
7 coagulation: prothrombin time, activated patrial
trhromboplastin time, thrombin time, fibrinogen
8 measure spleen size (cm below the costal margin)
9 height
10 pubertal development according to Tanner stage
11 scoring system (Appendix I)
12 samples for research studies
Determine phase of disease
In addition to accurate diagnosis, the definitive management
of CML is based on the phase of the disease at presentation.
WHO and European LeukaemiaNet (ELN) have slightly dif-
ferent criteria, the latter (Table I) being the one most used
by recent studies (Baccarani et al, 2006).
Immediate management
1 treat bleeding/infection, if present
2 consider leucaphaeresis if evidence of leucostasis
3 start allopurinol (10 mg/kg; max 300 mg) and ensure
good hydration. Allopurinol should only be necessary if
the WBC count is >20 9 109/l.
4 start hydroxycarbamide 25–50 mg/kg per d as a single
daily dose (syrup available) until diagnosis of CML con-
firmed, if required
5 start imatinib once diagnosis confirmed
Leucaphaeresis and back-up of autologous cells
There are few data (either paediatric or adult) that specifi-
cally address indications for leucaphaeresis in CML. As with
other leukaemias clinical evidence of leucostasis, rather than
WBC count, should be the indicator for therapeutic leuc-
aphaeresis. However, leucostasis is unusual in CML at WBC
counts <200 9 109/l. Therapeutic leucaphaeresis should be




Leucaphaeresis for storing autologous ‘back up’ stem cells
is no longer required. Autologous bone marrow cells may
still be useful and a bone marrow harvest or peripheral blood
stem cell collection may be performed once major molecular
Table I. European LeukaemiaNet (ELN) criteria for disease phase in
CML (adapted from Baccarani et al, 2006).






Blast cells 15–29% in
PB or BM














AP, accelerated phase; BC, blast crisis; BM, bone marrow; PB,
peripheral blood.
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response (MMR) or if possible, complete molecular remis-
sion (CMR) has been achieved (Bashir et al, 2010). The main
reason for cryopreserving autologous haemopoietic cells in
childhood CML is the risk of graft failure following alloge-
neic blood and marrow transplantation (BMT) or donor
lymphocyte infusion (DLI). This occurs in <5% sibling bone
marrow transplants; <10% of volonteer unrelated donor
BMT and in up to 20% of DLI, if DLI is delayed until hae-
matological relapse. Hence, if BMT is being considered stor-
age of autologous bone marrow cells can be considered at
best possible point of response to therapy.
Cryopreservation of sperm and oocyte vitrification
This should be considered and discussed with all boys of
appropriate age and performed at diagnosis. The risk of terato-
genicity for boys receiving imatinib appears very low and the
current advice is to continue on treatment at the time of con-
ception (Apperley, 2009a). However, there is no data on sec-
ond generation tyrosine kinase inhibitors (TKIs) and there is
no guarantee that the patient will achieve an optimal response,
hence avoiding the need to proceed to BMT or second genera-
tion (2G) TKI. In addition, there is experimental data from
animal studies suggesting that long-term imatinib may lead to
reduced testes size and sperm mobility (Nurmio et al, 2007).
If possible, sperm collection should occur before the initi-
ation of treatment, particularly before the use of hydroxycar-
bamide. If this is not possible, it should occur once the
patient is on imatinib treatment and at least 3 months after
the last dose of hydroxycarbamide.
Oocyte vitrification can be considered in post-menarche
young women if BMT is being considered.
Definitive management of CML
The management of CML is based on the phase of the disease
at presentation and response levels (Table II), as these are
measures of leukemic cell burden and early surrogate markers
of survival (Baccarani et al, 2006). Specific response levels
must be achieved at determined time-points, milestones, of
treatment depending on the TKI used (imatinib or 2G TKI).
Specific milestones are discussed in the relevant TKI section.
The combination of complete cytogenetic response (CCyR)
and partial cytogenetic response (PCyR) constitutes major
cytogenetic response. Monitoring should be carried out in cer-
tified laboratories only according to harmonized methodology
(Hughes et al, 2006). Standardized definitions of molecular
response should be used (Cross et al, 2012).
Treatment options
Imatinib
Imatinib remains the TKI of choice for the initiation of
treatment. It is the agent for which more extensive data
exists including the paediatric population, particularly when
used as first line therapy. Used in this way, prognostic factors
are well understood and allows the generation of time points,
milestones, to evaluate the response to treatment. If CCyR is
achieved, the pre-treatment risk score of prognostic classifica-
tions does not affect the progression-free survival (PFS). In
addition, prior treatment with imatinib does not affect nega-
tively the outcome of allogeneic BMT (Lee et al, 2008).
Summary of results with imatinib: with a follow-up of
7 years, the International Randomized Study of Interferon
and STI571 (IRIS) study showed that 5% patients had dis-
continued imatinib due to adverse events, 15% due to lack
of efficacy and 20% for other reasons. However, 83% of
those achieving CCyR maintained the response (Hughes
et al, 2010). The 6-year event-free survival (EFS), PFS and
overall survival (OS) were 83%, 93% and 88% (95% if CML
related deaths only included), respectively. A plateau was
achieved from the 4th year onwards with an event rate of
03–2% (Hochhaus et al, 2009). In the IRIS study, patients
who achieved MMR by 18 months had 100% freedom from
progression to AP/BC and 95% EFS at 7 years with only a
3% probability of loss of CCyR compared with 26% for
patients with CCyR but no MMR (Hughes et al, 2010). The
ELN consensus document (Baccarani et al, 2009) and others
have demonstrated that increasing the dose of imatinib pro-
duced no difference in the molecular response at 12 months,
even if the response was quicker at higher doses. A partial
cytogenetic response at 12 months (1–35% Ph+ metaphases)
has a significantly poorer PFS (De Lavallade et al, 2008).
Paediatric data: treatment of childhood CML with imati-
nib as first line agent in different trials (n = 150) has shown
that in CP 96% achieve complete haematological response
(CHR) and 69% CCyR at 12 months (Suttorp et al, 2009a).
The French CML IV study (n = 44) showed 86% CHR at
Table II. Response levels in the monitoring of treatment in CML












WBC <10 9 109/l CCyR 0%
Basophils <5% PCyR 1–35%











CHR, complete haematological response; CCyR, complete cytogenetic
response; PCyR, partial cytogenetic response; WBC, white blood
cells.
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3 months and 62% CCyR at 12 months. Thirty-one percent
achieved MMR at 12 months and with a median follow-up
of 31 months the PFS of this cohort was 98%. However,
20% had discontinued imatinib, mainly because of subopti-
mal response. The most common side effects were neutrope-
nia and musculoskeletal events (Millot et al, 2011).
Imatinib-treated patients show a biphasic molecular
response. There is a rapid initial drop in the level of
BCR-ABL1, reflecting the clearance of mature CML progeny,
followed by a second phase with a shallow gradient reflecting
the gradual depletion of the less-sensitive CML granulocyte-
macrophage precursor pool, which is relatively resistant to
imatinib (Roeder et al, 2006). Approximately, 40% patients
with a stable CMR for at least 2 years are able to stop
imatinib and remain in molecular remission for at least
2 years. Molecular relapse occurred in around 60% of the
patients after a median interval of 4 months, and relapses
after 6 months are uncommon, but can still occur (Mahon
et al, 2010). Stopping imatinib is not recommended outside a
clinical trial. The STOPIMaPED (an international collabora-
tive study to discontinue Imatinib/Glivec in paediatric CML
patients with sustained complete molecular response) study is
currently in preparation in order to address the question of
discontinuation in the paediatric population (E. de Bont,
University Medical Centre Groningen, Groningen, NL).
Dosage and administration. Two hundred and sixty to
340 mg/m2 orally once daily gives drug exposure similar to
400–600 mg adult dosage. It is usual to take it in the morn-
ing with breakfast, though some patients prefer it before
going to sleep to avoid nausea. Imatinib is a local irritant,
therefore it ought to be taken in a sitting position with a
large glass of water or apple juice (minimum 100 ml). Tab-
lets may be dispersed in water or apple juice using 50 ml for
100 mg tablet, 200 ml for 400 mg tablet. The contents must
be stirred until dissolved and used immediately. For children
<3 years of age it is recommended that at least 120 ml of
water or food (i.e. yoghurt or apple puree) are taken to
avoid oesophageal irritation.
The starting dose is:
1 CP: 260–300 mg/m2 (maximum absolute dose 400 mg)
2 AP: 400 mg/m2 (maximum absolute dose 600 mg)
3 BC: 500 mg/m2 (maximum absolute dose 800 mg)
The dose should be calculated to the nearest 100 mg,
which is the size of the smallest tablet and preferably
upwards, if tolerated, as active metabolites have a shorter
half-life in children than in adults and patients with low
plasma levels are less likely to achieve CCyR (Picard et al,
2007). Female teenagers must be advised to avoid conception
while taking imatinib because of the rate of serious fetal
abnormalities is higher than expected (Apperley, 2009b).
If on hydroxycarbamide, this should be stopped once hae-
matological control, not normalization, is achieved. Imatinib
and hydroxycarbamide can be used concomitantly, imatinib
should be introduced as soon as the diagnosis of CML has
been confirmed.
The WBC count usually starts to fall in 1–2 weeks and
normalizes in 6 weeks. Platelet counts usually normalize after
1–3 weeks, but can take 3–6 weeks if the platelet count is
>700 9 109/l.
Management of toxicity. Imatinib toxicity is common but
the effects are generally mild to moderate. Side effects in
children occur with the same or less frequency and are less
severe than in adults (Bond et al, 2008; Mauro & Deininger,
2009). In the largest series (Millot et al, 2006) the common-
est toxicity was neutropenia and thrombocytopenia; non-
haematological toxicity was seen in 50% and was mainly
infection, skin rashes, nausea and vomiting.
Myelosuppression occurs in a quarter of CP patients
(50% of AP) especially in the first 6 weeks, a rate higher
than seen in adults. 27%, 5% and 25% developed grade 3
or 4 neutropenia, thrombocytopenia and anaemia, respec-
tively (Millot et al, 2011). Management may be difficult and
should be discussed with experienced colleagues as reduced
doses appear to reduce the chance of CCyR and a change
in blood counts may indicate disease progression or drug
interaction.
1 anaemia: should be managed by transfusion (or erythro-
poietin) rather than dose reduction.
2 neutrophils <10 9 109/l: stop for up to 2 weeks; restart
when neutrophils >10 9 109/l. Consider adding granulo-
cyte colony-stimulating factor (G-CSF) if persistent neu-
tropenia and still in CP. Restart imatinib at full dose if
neutropenia <2 weeks, otherwise reduce dose by 20%.
3 platelet counts <50 9 109/l: stop; restart when platelets
>100 9 109/l. Reduce dose by 20% if recurrent.
Gastro-intestinal (GI) symptoms are common, particularly
nausea in the first weeks of treatment. Strategies to overcome
this include adding an antiemetic, such as ondansetron, and
taking imatinib before going to bed. Imatinib bioavailability
is not significantly affected by the administration of food,
except grapefruit juice.
Frequent side effects:
1 oedema/fluid retention: consider oral diuretic, if severe
pleural effusion (rare occurrence) thoracocentesis and
brief course of steroids
2 muscle cramps: supportive, consider calcium/magnesium
repletion
3 bone pain: affects 10% of children and lessens with longer
therapy, manage with non-steroidal anti-inflammatory
agents
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Less frequent side effects:
1 abnormal liver function tests (occasionally severe hepato-
toxicity: monitor if concomitant use of paracetamol)
Drug interactions: because of the inherent risk of either
reduced activity or enhanced toxicity of the concomitant
medication and/or imatinib, drugs known to interact with
the same CYP450 isoenzymes (2D6 and 3A4) as imatinib
should be used with caution (see Appendix II).
Bone metabolism and longitudinal growth—There is evidence
in animal studies (Vandyke et al, 2009), clinical cases (Millot
et al, 2009; Schmid et al, 2009) and prospective studies (Gi-
ona et al, 2013) that imatinib dysregulates bone remodelling.
In adults, imatinib is well known to cause hypocalcaemia
and hypophosphataemia, but there is evidence of exhibiting
a different effect on bone metabolism than that encountered
in children (Fitter et al, 2008; Shima et al, 2011; Jaeger et al,
2012). Children, particularly if treatment is initiated when
prepubertal, are at an increased risk of impaired bone
remodelling, which may result in growth retardation or arrest
(Suttorp & Millot, 2010) with highly significant reduction in
height standard deviation scores, possibly due to the alterna-
tive targets of imatinib, KIT and PDGFR (Bansal et al, 2012).
There is also a recent report of acquired growth hormone
deficiency as the cause of loss in longitudinal growth as an
alternative cause to downstream targets (Hobernicht et al,
2011). The optimal approach to children suffering from this
side effect remains to be defined. Any decision to stop TKI
therapy should only be taken as part of a study.
Potential cardiotoxicity—There is potential cardiotoxicity of
imatinib due to inhibition of ABL1 in cardiac tissue, which
has been shown to have detrimental effects on the viability
of cardiomyocytes in animal models, but in large cohorts of
adult patients this appears to be very rare (Kerkela et al,
2006). Although there is no current evidence that this should
influence clinical decision-making, it might be an issue of
concern for long-term therapy in children.
Monitoring. Routine monitoring for toxicity:
1 Full blood count, reticulocytes, urea, electrolytes, creatinine,
liver function tests, calcium, phosphate and magnesium:
a 1st 4 weeks: weekly
b 2nd and 3rd month: every 2 weeks
c 4th to 6th month: every 4 weeks
d 7th month to 1 year: every 6 weeks
e After 1 year: every 3 months






a DEXA (dual-energy X-ray absorptiometry) scan
Monitoring disease response:
1 Bone marrow aspirate/cytogenetics (FISH for BCR-ABL1
may be used if Giemsa-banding fails): every 3 months
until CCyR, then only if loss of response or myelodysplas-
tic changes.
2 Quantitative PCR for BCR-ABL1 on peripheral blood
every 3 months
Milestones and response. Substantial experience acquired
with imatinib has allowed the identification of specific
response levels at particular time-points of treatment, repre-
senting disease burden and predictive of long-term outcomes.
This has been developed by the ELN (Baccarani et al, 2009)
and has been modified to include more recent findings
regarding molecular responses (Table III). Optimal response
indicates that change in therapy is unlikely to improve sur-
vival. In CP with imatinib as first line treatment, this is pro-
jected to be close to 100% after 6–7 years. Failure to achieve
the specified response level at a specific milestone constitutes
a suboptimal response or failure and warrants change of
treatment.
The ELN criteria have been independently validated. The
rate of combined suboptimal response and failure in newly
diagnosed patients is 37% at 3 months (25% if BCR-ABL1
<10% criteria, which was not part of the original criteria
used), 129% at 6 months, 208% at 12 months and 421%
at 18 months (Marin et al, 2008). There are no similar data
for children. However, similar responses can be derived from
paediatric studies. The German CML-PAED II study (n = 61,
56 in CP) showed that of those entering the study in CP, 5%
(2/42) of patients failed to achieve CHR at 3 months, 7% (2/
28) failed CCyR at 12 months and 15% (2/19) had a subop-
timal molecular response at 18 months (Suttorp et al,
2009a). Overall 15% patients stopped imatinib, 10% because
of insufficient response and 5% because of toxicity. Ten per-
cent (5/56) achieved CMR (9–33 months). However, this was
an early analysis and follow-up was limited. Data from the
French CML-IV paediatric trial for newly diagnosed patients
in CP with a median follow-up of 33 months, encountered a
substantially higher rate of suboptimal responses with only
86% achieving CHR at 3 months, 61% of patients achieving
a CCyR at 12 months, and a rate of MMR of 57% similar
(though not necessarily at 18 months) to the findings in
adults. Thirty percent patients discontinued imatinib, <5%
due to toxicity (Millot et al, 2011).
The molecular response at 3 months, used for discriminat-
ing long-term outcome for adult patients treated with TKIs,
has been identified by two independent groups (Hanfstein
et al, 2012; Marin et al, 2012). BCR-ABL1 transcript levels
>10% identify a high-risk group of patients with a signifi-
cantly lower OS and PFS.
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Clonal cytogenetic abnormalities in Ph+ cells (CCA/Ph+)
is a ‘warning’ factor at diagnosis. Major route additional
cytogenetic abnormalities (second Ph chromosome, trisomy
8, isochromosome 17q or trisomy 19) have a negative impact
on survival and PFS (Fabarius et al, 2011). The prognosis for
patients with clonal cytogenetic abnormalities in Ph negative
cells (CCA/Ph) is driven by response to imatinib in the
absence of morphological evidence of myelodysplastic syn-
drome (MDS) and therefore it is a warning sign requiring
monitoring with 3 monthly BM aspirates, rather than a crite-
ria to change treatment (Deininger et al, 2007).
Significance of changes in transcript levels: fluctuation in
BCR-ABL1 transcript levels does not necessarily have a clini-
cal implication and/or anticipate a loss of response to imati-
nib. Two to fivefold change (up to 05-log) is within the
variability of the technique (Kantarjian et al, 2008). At very
low transcript levels, this can be the result of sampling effect.
However, a rise >005% is almost certainly real. A rising level
is associated with a greater risk of a tyrosine kinase domain
(TKD) mutation acquisition and resistance (Soverini et al,
2005). Confirmation is required in at least an independent
sample a month apart and it is better to establish a trend of
increase resulting from two consecutive rises. If the rise is
>005%, but there is no loss of MMR, mutation analysis
should be performed. However, a rise in BCR-ABL1 tran-
script levels in those who concomitantly lose MMR is a
reproducible predictor for loss of CCyR and is a suboptimal
response (Kantarjian et al, 2009; Marin et al, 2009). There is
a higher incidence of cytogenetic relapse among patients who
never achieved a MMR and had a 10-fold increase of tran-
script levels (Cortes et al, 2005).
Lack of compliance is the single most frequent factor for
loss of CCyR in long-term imatinib-treated patients (Ibrahim
et al, 2011) and should be carefully checked at any evalua-
tion, particularly when dealing with patients in adolescence.
Where available, performing imatinib plasma levels and
monitoring of imatinib to target a concentration of imatinib
above 1000 ng/ml could be the first step if there is a subopti-
mal response (Cortes et al, 2009).
Treatment with second generation TKIs
Randomized phase 3 studies have recently demonstrated the
superiority of both dasatinib and nilonib in the achievement
of both CCyR and MMR (Kantarjian et al, 2010, 2012; Saglio
et al, 2010a). However, it is still not known whether this
translates into superior long-term OS and PFS. Importantly,
approximately 50% of patients who are intolerant or resistant
to imatinib achieve CCyR with 2G TKIs (Shah et al, 2010).
There are limited data about the use of dasatinib in children;
these children should be enrolled in opened trials if possible
(i.e. the BMS phase 2 trial CA180-226). In a phase 1 trial all
eight evaluable patients had a response, including three
CCyR and three partial cytogenetic remissions (PCyR; Aplenc
et al, 2011). Information on nilotinib is limited, but soon
expected to be available from a current phase I trial. Dasati-
nib is associated with the development of pleural effusions
(observed in 302% of patients older than 60 years of age)
and nilotinib carries a warning regarding QT prolongation
and sudden death (Latagliata et al, 2012). Pancreatitis has
been described with the use of nilotinib.
There has been a phase 3 study of dasatinib in BC of CML
(Saglio et al, 2010b). In myeloid BC, 25% patients achieved a
major CyR (CCyR and PCyR) at a median time of 29 months
with a median duration of 77 months. In lymphoid BC, 50%
patients achieved a major cytogenetic remission (MCyR) at a
median time of 14 months with a median duration of
4 months. The OS rate at 2 years was 24–28% for patients
with myeloblast crisis and 16–21% for patients with lymphoid
BC. Dasatinib crosses the blood–brain barrier and shows
Table III. Modified ELN guideline for optimal treatment response to imatinib in CML (Baccarani et al, 2009, 2013).
Time Optimal response Suboptimal response Failure Warnings





Less than CHR N/A
6 months At least PCyR Less than PCyR No CyR N/A
12 months CCyR PCyR Less than PCyR Less than MMR
18 months MMR Less than MMR Less than CCyR N/A
Any time Stable or improving MMR Loss of MMR
Mutations†
Loss of CHR
Loss of CCyR, Mutations‡
CCA/Ph+*
Increase in transcript levels ≥ 005%
CCA/Ph
CCA, clonal cytogenetic abnormalities in either Philadelphia positive (CCA/Ph+) or negative cells (CCA/Ph), as indicated; CHR, complete hae-
matological response; CyR, cytogenetic response; ELN, European LeukemiaNet; MMR, major molecular response; N/A, not applicable; PCyR, par-
tial cytogenetic response.
*CCA/Ph+ (clonal cytogenetic abnormalities in Philadelphia positive cells) is a ‘warning’ factor at diagnosis, although its occurrence during treat-
ment, i.e. clonal progression, is a marker of treatment failure. Two consecutive cytogenetic tests are required and must show the same clonal
cytogenetic abnormalities in at least two Ph+ cells.
†TKD mutations still sensitive to imatinib.
‡TKD mutations poorly sensitive to imatinib.
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long lasting responses in Ph+ central nervous system disease
(Porkka et al, 2008).
Dosage and administration. Dasatinib: the dose of dasatinib
is 60–80 mg/m2 per d (routine dose in adults 100 mg once
daily). Tablets can be allowed to dissolve over 20 min in
30 ml lemonade, preservative-free apple or orange juice.
After ingestion, rinse the residue off the glass with 15 ml of
the juice and administer. For patients in CP with suboptimal
response or failure to imatinib use 60 mg/m2 once daily, for
patients in AP/BC use 80 mg/m2 in two divided doses (maxi-
mum dose in adults: 140 mg divided in two doses).
Nilotinib: the paediatric dosing for nilotinib is yet to be
established (phase 1 trial ongoing).
Milestones and response. The responses at specific milestones
have also been developed by the ELN (Baccarani et al, 2009,
2013), but differ from those for imatinib (Table IV).
BMT
OS ranges from 60% to 80% with better results in matched
sibling donors (87%) compared with matched unrelated
donors (59%). Despite the role of graft-versus-leukaemia
effect, the transplant-related mortality is lower and best
results are obtained when graft-versus-host disease (GvHD)
grade II–IV does not occur (OS of 91% and 69% for sibling
and unrelated donors, respectively Cwynarski et al, 2003).
No significant differences in OS for both related and unre-
lated transplantation have been found when comparing total
body irradiation with busulfan/cyclophosphamide condition-
ing regimens (Suttorp et al, 2009b). MCyR at the time of
BMT, as achieved by prior imatinib treatment, predicts an
excellent 5-year OS of 819%, at least in the unrelated setting
(Muramatsu et al, 2010).
In the European Group for Blood and Marrow Transplan-
tation study, children transplanted in AP had an OS of 46%
and 39%, EFS of 35% and 34%, relapse rate of 49% and
20% and transplant-related mortality of 16% and 46% for
sibling and unrelated transplantation, respectively (Cwynarski
et al, 2003).
Tyrosine kinase domain mutations
There are >90 different mutation involving different amino
acids reported, though only a subset are associated with TKI
failure. BCR-ABL1 kinase domain mutations are not induced
but arise independently and are selected by TKIs (Roche-
Lestienne et al, 2002). They may theoretically pre-exist before
the start of therapy and have been reported only in some
cases with advanced-phase disease (Willis et al, 2005).
Monitoring
Given that <3% of CP patients develop a mutation (Khora-
shad et al, 2008), routine mutation monitoring of CP
patients with optimal response during therapy is not recom-
mended. Therefore TKD mutation analysis is reserved for
treatment failure or suboptimal response. Development of a
mutation predicts the loss of CCyR. Overall, a third of
patients who fail imatinib treatment and 16% with subopti-
mal response harbour a mutation (Baccarani et al, 2006) and
this information should direct treatment modification.
Sensitivity of mutation analysis by direct sequencing is
15–25% (Soverini et al, 2004), which can be improved if pre-
ceded by denaturing high performance liquid chromatogra-
phy (HPLC) to 1–10% (Deininger et al, 2007). The relative
sensitivity of different methods is not a limitation because,
so far, low level mutations (<20%) have not been proven to
be of clinical significance in predicting resistance and disease
progression. Mutations found in rare Ph+ cells are not neces-
sarily selected and able to sustain long-term haemopoiesis
(Sherbenou et al, 2007; Soverini et al, 2011).
Mutation analysis should be performed in the following
instances, having first ruled out non-adherence to treatment,
particularly in teenagers:
1 At diagnosis: AP/BC patients only
2 First line imatinib therapy: treatment failure and subopti-
mal response
3 Second line dasatinib or nilotinib therapy: haematological
or cytogenetic failure
When selecting a TKI based on the results of in vitro
sensitivity testing, it must be kept in mind that there are
Table IV. Modified ELN guidelines for optimal treatment response


























CCA, clonal cytogenetic abnormalities in either Philadelphia positive
(CCA/Ph+) or negative cells (CCA/Ph), as indicated; CHR, com-
plete haematological response; CCyR, complete cytogenetic response;
CyR, cytogenetic response; ELN, European LeukemiaNet; MMR,
major molecular response; N/A, not applicable; PCyR, partial cytoge-
netic response; 2G TKI, second generation tyrosine kinase inhibitor.
*CCA/Ph+ (clonal cytogenetic abnormalities in Philadelphia positive
cells) is a ‘warning’ factor at baseline, although its occurrence during
treatment, i.e. clonal progression, is a marker of treatment failure.
Two consecutive cytogenetic tests are required and must show the
same clonal cytogenetic abnormalities in at least two Ph+ cells.
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ongoing controversies with regard to the simple use of tables
listing mutations and 50% inhibitory concentration (IC50)
values. Some experts believe that the latter on its own should
not guide physician choices for therapy (Khorashad et al,
2006; Redaelli et al, 2009; Laneuville et al, 2010; Branford &
Hughes, 2011). Data from in vitro analyses do not account
for factors relevant in vivo, such as protein binding and
activity of cellular influx/efflux pumps or a variety of other
factors affecting clinical response to a 2G TKI, and thus gen-
erally provide an inadequate predictability of treatment
response (Bixby & Talpaz, 2011).
As performing a mutation analysis may require some time,
we recommend the following pragmatic approach once
imatinib resistance based on rising BCR-ABL1 transcript
levels is suspected:
1 rule out non-adherence to treatment (clinical history,
determination of serum drug level if available)
2 collect blood for mutation analysis, perform bone marrow
aspiration for cytogenetic analysis
3 switch treatment to a 2G TKI
4 4 weeks later, repeat determination of BCR-ABL1 blood
transcripts level
5 interpret findings of cytogenetic analysis and mutation
analysis in the light of the BCR-ABL1 in vivo response
rate to the chosen 2G TKI
Management of mutations in patients on imatinib
For the most frequent BCR-ABL1 gene mutations (i.e.
M244V, G250E, Y253F/H, E255K/V, T315I, F317L, M351T,
E355G, F359V and H396R/P) clinical and laboratory (IC50)
experience is that imatinib treatment is no longer advised.
However, the possibility of constitutional single nucelotide
polymorphisms or a bystander effect not contributing to the
mechanism of resistance has to be considered for rare or
unreported mutations with unknown IC50 and therapy man-
aged according to response. Imatinib-resistant patients har-
bouring a TKI mutation have a higher likelihood of
developing additional mutations under the selective pressure
of the novel TKI: 45% achieved and subsequently lost
response with evidence of newly acquired mutations (Sove-
rini et al, 2009). Hence, sibling and unrelated BMT is indi-
cated in this situation, but an attempt to achieve major CyR
or best possible response with a 2G TKI beforehand should
be sought (see algorithm, Section 6).
2G TKIs have a narrower spectrum of mutations retaining
insensitivity and is non-overlapping except for BCR-ABL1
T315I. Best available treatment for patients with no suitable
related or unrelated donor is (Soverini et al, 2011):
1 BMT always or investigational drug: BCR-ABL1 T315I
2 Dasatinib rather than nilotinib: BCR-ABL1 Y253H, BCR-
ABL1 E255K/V and BCR-ABL1 F359V/C/I
3 Nilotninb rather than dasatinib: BCR-ABL1 V299L, BCR-
ABL1 T315A and BCR-ABL1 F317L/V/I/C
4 Dasatininb and nilotinib equally effective: other mutations
Treatment algorithms according to phase
Chronic and accelerated phase
The treatment algorithms according to phase incorporate the
evidence presented in previous sections and take into
account the specific character of CML treatment in child-
hood: the need to balance the importance of cure, which at
present is only proven for BMT, and the potential for leukae-
mic stem cell depletion in the long-term with the use of TKIs
and novel agents (Figs 1 and 2). As the incidence of CML is
greatest in the teenage years, the forthcoming availability of
therapeutic agents licensed or approved as part of studies for
use in adults needs to be taken into account as the young
person grows and may become a candidate to use them.
When a 2G TKI is indicated at present, unless otherwise
indicated because of a TKI mutation, dasatinib is the agent
of choice. This recommendation reflects the limited experi-
ence with dasatinib from a phase II trial and unpublished
phase I trial experience with nilotinib.
There are circumstances in the context of CML in child-
hood and young people when BMT is the most appropriate
modality of treatment and hence an acceptable deviation
from the algorithms (Fig 2). These comprise:
1 lack of compliance despite maximum support
2 serious side effects inherent to all TKIs
3 patient choice of balancing the risk of BMT versus the
probability of achieving a definitive cure following appro-
priate counselling
Blast crisis
BC is usually either myeloid (60–80%) or lymphoid (20–
30%), but a mixed-lineage phenotype can occur and, rarely,
patients may present in BC without a diagnosed preceding
CP and discrimination from Ph+ acute leukaemia may be
impossible.
Treatment with a 2G TKI according to TKD mutation
and combined with chemotherapy should be given and allo-
BMT planned as quickly as possible (Fig 3), preferably within
3 months (Hehlmann, 2012). Most long-term survivors in
BC have received an allograft, mostly in second CP (Saussele
et al, 2010) and obtaining a second CP is the most important
prognostic factor for survival (Wadhwa et al, 2002). Acute
lymphoblastic leukaemia and acute myeloid leukaemia induc-
tion according to type of BC are suitable regimens (Hehl-
mann, 2012). If lymphoid crisis, it requires the addition of
six doses of intrathecal chemotherapy. Following BMT, the
patient could be restarted on 2G TKI as early day +30 pro-
vided there is adequate engraftment, and maintained thereaf-
ter for a prolonged period (Klyuchnikov et al, 2010). The
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Fig 2. Algorithm for treatment of CML in
Accelerated Phase. BMT, bone marrow trans-
plantation; CML-AP, chronic myeloid leukae-
mia in accelerated phase; CyR, cytogenetic
response; HLA, human leucocyte antigen;
TKD, tyrosine kinase domain; 2G TKI, second
generation tyrosine kinase inhibitor.
Fig 1. Algorithm for treatment of CML in Chronic Phase. BMT, bone marrow transplantation; CML-CP, chronic myeloid leukaemia in chronic
phase; CyR, cytogenetic response; HLA, human leucocyte antigen; TKD, tyrosine kinase domain; T315I mutation, BCR-ABL1 T315I; 2G TKI, sec-
ond generation tyrosine kinase inhibitor.
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BCR-ABL1/ABL1 ratio should be monitored 3 monthly until
undetectable, then 6-monthly (Hehlmann, 2012).
Compliance
The half-life of imatinib is in the region of 18 h, thus lack of
compliance for just 1 week would completely eliminate the
drug from plasma (Cortes et al, 2009). Therefore, non-adher-
ence to TKI treatment is a potential cause of treatment failure
or suboptimal response, of particular relevance for our patient
population as the incidence of CML is most frequent in adoles-
cence. In fact, even in adult patients it has been established as
the single most frequent factor for suboptimal responses, loss
of CCyR in long-term imatinib-treated patients and achieving
molecular responses (Noens et al, 2009; Marin et al, 2010;
Ibrahim et al, 2011). Before making any treatment decisions
compliance should be thoroughly investigated as part of the
clinical history and, where available, performing imatinib
plasma levels. Imatinib should be targeted to a concentration
above 1000 ng/ml and this could be the first step if there is a
suboptimal response (Cortes et al, 2009).
Imatinib and pregnancy
Animal data suggest that imatinib at standard dosages is
unlikely to impair fertility in either adult males or females,
but human data remains limited (Schultheis et al, 2012).
Children born to men who are actively taking imatinib at the
time of conception appear healthy and current advice is not
to discontinue treatment. In contrast, the data relating to
children born to women exposed to imatinib during preg-
nancy are less encouraging (Apperley, 2009a,b). In one study,
50% (63 of 125) of women treated with imatinib gave birth
to healthy babies (Pye et al, 2008). However, 12 infants
exposed to imatinib during the first trimester had congenital
abnormalities, especially of the kidneys, skeleton, heart, brain
and gut (i.e. exomphalos). For female patients with a pro-
longed MMR, substitution of TKI with IFN-a is recom-
mended (Ali et al, 2004; Burchert et al, 2010) and for
patients with an inferior response, pregnancy should be post-
poned or to the TKI should be substituted with IFN-a dur-
ing the first trimester and TKI readministered in the second
or third trimester (Brenner et al, 2012). The effect of imati-
nib cessation on disease course is still under study, but most
studies report disease relapse after imatinib discontinuation,
with only a fraction of patients achieving complete remission
after readministration of imatinib (Ault et al, 2006). How-
ever, for those patients with durable CMR (at least 2 years) a
more favourable situation exists, with studies demonstrating
disease control following reintroduction of TKI (Mahon
et al, 2010). At present the data on 2G TKIs is too limited to
make specific recommendations, but they also seem terato-
genic (Cortes et al, 2008).
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Appendix l
Scoring systems applied for CML chronic phase at diagnosis in adult patients
Scorings systems established in adult medicine to estimate the risk of progression in CML CP during subsequent treatment. This
can be applied at diagnosis only and scoring must be performed before any treatment is commenced [Sokal: treatment with
hydroxycarbamide; Hasford: treatment with interferon-alpha; EUropean Treatment Outcome Study (EUTOS): treatment with
imatinib].
Sokal score*,† Sokal score young adults*,‡ Hasford/EURO score†,§ EUTOS score†
Variables, unit
Age, years 00116 9 (age 434) 06666 [if age >50 years]
Spleen, cm below
costal margin







+10956 [if platelets >1 500 000]
Blood blasts, % +00887 9 (blasts 21) +00324 9 (blasts 222) +00584 9 blasts
Blood basophils, % +02039 [if basophils >3] +(7 9 basophils)
Blood eosinophils, % +00413 9 eosinophils
Haematocrit (Hct) 00173 (Hct 342)
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Appendix I . (Continued)
Sokal score*,† Sokal score young adults*,‡ Hasford/EURO score†,§ EUTOS score†
Relative risk
Low risk <08 <08 <780 ≤87
Intermediate risk 08–12 08–12 781–1480
High risk >12 >12 >1480 >87
*Sokal risk is expressed as exponential of the total.
†Calculator available online at http://www.leukemia-net.org/content/leukemias/cml/cml_score/. The main differences between the
EURO and Sokal scores concern age (it is more important in the Hasford/EURO than in Sokal), spleen size, and the percentage
of blasts in peripheral blood (more important in Sokal than in Hasford/EURO).
‡Calculated from a cohort of 625 patients (25 patients <16 years; 249 patients aged 16–30 years and 351 patients aged 31–-
45 years): survival was 60 years for the low risk group, 48 years for the intermediate risk group and 30 years for the high risk
group (Sokal et al, 1985).
§Hasford risk is expressed as the total 9 1000.
Appendix ll
Imatinib drug interactions
Drugs known to interact with the same CYP450 isoenzymes (2D6 and 3A4) as imatinib should be used with caution. Special care
has to be given to the concomitant use of paracetamol. Prophylactic anti-emetics should be withheld until the patient has experi-
enced grade 1 nausea or vomiting.
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